Regeneron Pharmaceuticals, Inc.

Charles Paulding

Lorah Perlee

Sara Hamon

Aris I Baras

Amy Damask

Luca Andrea Lotta

Manuel Allen Revez Ferreira

Goncalo Abecasis

Julie Horowitz

Garen Manvelian

Michael Cantor

The present disclosure provides methods of treating subjects having sepsis, SIRS, septic shock, and/or MODS, methods of identifying subjects having an increased risk of developing sepsis, SIRS, septic shock, and/or MODS, and methods of detecting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and/or Low Density Lipoprotein Receptor (LDLR) variant nucleic acid molecules and variant polypeptides.

Treatment of sepsis with PCSK9 and LDLR modulators

The present disclosure provides methods of reducing cardiovascular risk by administration of a PCSK9 inhibitor to patients having a genetic profile associated with response to PCSK9 inhibitor therapy.

Genome-based methods for reducing cardiovascular risk

Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

Growing community of inventors

Tarrytown, NY, United States of America

Charles Paulding